c-Myc tag Peptide (A6003): Precision Reagent for Immunoassay and Cancer Research

Executive Summary. The c-Myc tag Peptide (SKU A6003) from APExBIO is a synthetic decapeptide corresponding to amino acids 410-419 of human c-Myc, optimized for displacing c-Myc-tagged fusion proteins in immunoassays (APExBIO product page). It achieves specific inhibition of anti-c-Myc antibody binding, facilitating cell signaling and cancer biology research (Wu et al., 2021). The peptide is highly soluble in DMSO (≥60.17 mg/mL) and water with ultrasonic treatment (≥15.7 mg/mL), but insoluble in ethanol under standard laboratory conditions. c-Myc is a proto-oncogene encoding a transcription factor involved in cell proliferation, apoptosis, and gene amplification, making this peptide a key tool for dissecting regulatory pathways in oncology (related guide). Proper storage at -20°C in a desiccated state preserves peptide stability for reproducible results.

Biological Rationale

The c-Myc protein is a master regulatory transcription factor implicated in cell cycle progression, apoptosis, differentiation, and stem cell self-renewal (Wu et al., 2021). Aberrant c-Myc activation is a hallmark in diverse human cancers, driving uncontrolled proliferation and altered metabolic states. The c-Myc tag Peptide mimics the C-terminal epitope of c-Myc, enabling displacement of c-Myc-tagged fusion proteins bound to anti-c-Myc antibodies in immunoassays (see protocol guide). This approach allows for the precise study of c-Myc’s role in transcriptional regulation and post-translational modification, supporting investigations into gene amplification and signal transduction. The use of synthetic peptides as competitive inhibitors is a validated strategy for dissecting protein–protein interactions in basic and translational research (mechanism review).

Mechanism of Action of c-Myc tag Peptide

The c-Myc tag Peptide (EQKLISEEDL) acts by competitively binding to anti-c-Myc antibodies, thereby displacing c-Myc-tagged proteins in immunoassays. This competitive inhibition is sequence-specific, leveraging the high-affinity recognition between the synthetic peptide and the antibody’s paratope. Upon addition to an immunoassay, the peptide saturates available antibody binding sites, releasing c-Myc-tagged fusion proteins for subsequent analysis or elution (protocol optimization). This mechanism enables robust control over assay specificity and signal-to-noise ratio. The peptide’s amino acid sequence is identical to residues 410-419 of human c-Myc, ensuring minimal cross-reactivity with unrelated proteins.

Evidence & Benchmarks

• The peptide displaces c-Myc-tagged fusion proteins from immobilized anti-c-Myc antibodies in ELISA and pull-down assays with ≥95% efficiency at 10–100 μM concentrations (see DOI:10.1080/15548627.2020.1761653).
• Solubility tests confirm the c-Myc tag Peptide achieves ≥60.17 mg/mL in DMSO and ≥15.7 mg/mL in water (ultrasonic treatment, RT), but is insoluble in ethanol under identical conditions (product data).
• Competitive displacement is highly specific: no inhibition is observed with unrelated antibody/peptide pairs (protocol guide).
• c-Myc is validated as a proto-oncogene driving cell proliferation, apoptosis inhibition, and ribosomal gene upregulation in cancer models (DOI:10.1080/15548627.2020.1761653).
• Storage at -20°C (desiccated) maintains peptide integrity for ≥12 months, whereas aqueous solutions degrade within 7 days at 4°C (APExBIO).

Applications, Limits & Misconceptions

The c-Myc tag Peptide is optimized for use in immunoassays, including ELISA, Western blot, and affinity purification protocols. It is ideal for competitive displacement of c-Myc-tagged fusion proteins, enhancing assay specificity and enabling mechanistic studies of transcription factor regulation. The peptide supports the analysis of c-Myc-mediated gene amplification and signaling in cancer biology (mechanism review). However, it is not suitable for use as a therapeutic agent, in vivo imaging, or as a diagnostic reagent. The peptide must be handled under research-use-only conditions.

Common Pitfalls or Misconceptions

• The c-Myc tag Peptide is not intended for therapeutic or diagnostic use; its function is limited to in vitro research applications.
• It does not bind to other epitope tags (e.g., FLAG, HA); specificity is limited to anti-c-Myc antibodies.
• Aqueous peptide solutions are unstable beyond 7 days at 4°C; fresh solutions are required for reproducibility.
• The peptide is ineffective in ethanol-based buffers due to insolubility.
• It does not modulate native c-Myc transcription factor activity in intact cells or tissues; its effects are limited to antibody binding contexts.

Workflow Integration & Parameters

To integrate the c-Myc tag Peptide into immunoassay workflows, dissolve the peptide in DMSO (≥60.17 mg/mL) or water with ultrasonic treatment (≥15.7 mg/mL). For competitive displacement, add 10–100 μM peptide to the assay buffer and incubate for 30–60 minutes at room temperature. Eluted proteins can be analyzed by SDS-PAGE, Western blot, or mass spectrometry. Ensure all peptide stocks are stored desiccated at -20°C for long-term stability. Avoid repeated freeze-thaw cycles (scenario-based guide). This article extends previous optimization protocols by providing explicit solubility values, stability limits, and mechanistic details for advanced users.

Conclusion & Outlook

The c-Myc tag Peptide (A6003) from APExBIO is a validated research reagent for the displacement of c-Myc-tagged fusion proteins and precise anti-c-Myc antibody binding inhibition. Its sequence specificity, high solubility in DMSO and water, and robust competitive action make it indispensable in studies of transcription factor regulation and cancer biology. As peptide-based tools advance, the c-Myc tag Peptide will continue to facilitate mechanistic dissection of proto-oncogene pathways and support the development of next-generation immunoassay workflows. For further protocol development and troubleshooting, see Optimizing Immunoassays with c-Myc tag Peptide and the APExBIO product page.